Vaidya Sane Ayurved Laboratories Ltd
Vaidya Sane Ayurved Laboratories Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
3 of 4 strong
The short version
FY'27 revenue target: Rs. Targeting EBITDA margin of near 15% by FY 2027, progressing towards 20% margin by FY 2028. - Revenue expected to grow to Rs.
From Vaidya Sane Ayurved Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- FY'27 revenue target: Rs. 170-180 crores driven by higher patient additions, increased hospital utilization, and franchise clinic growth.
- Medium-term target (FY'28): Scale revenues towards Rs. 250-300 crores with about 50% of revenue coming from hospitals.
- Clinic revenue projected at Rs. 100-110 crores; hospital revenue Rs. 50-60 crores in FY'27.
- Patient inflow expected to grow steadily; marketing efforts focused on acquiring ~200,000 new patients annually by FY'28.
- ARPU growth expected to be marginal (5-10%) with single-digit ARPU growth in hospital segment.
- Expansion in hospital beds (e.g., Khopoli hospital to 150 beds by FY'28) supports revenue growth.
2 more points from Vaidya Sane Ayurved Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Vaidya Sane Ayurved Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Preferential allotment funds received are currently in Fixed Deposit (FD) and have not been utilized yet; expected full funding to arrive over about 12 months (Page 20).
- Planned Capex includes ongoing construction for expansion, particularly at the Khopoli hospital, currently at the third slab out of seven, aiming to complete before the upcoming rainy season (Page 20).
- Expansion plans also include Nagpur hospital, pending government permissions, and future bed additions across hospitals to target 250-300 beds (Page 20).
- Strategic investment via proposed acquisition of Parasnath Health Care OPC Private Limited to expand healthcare capabilities and integrated ecosystem (Page 4).
2 more points from Vaidya Sane Ayurved Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Vaidya Sane Ayurved Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention a current or expected order book or pending orders.
- The company is focusing on growing patient inflows, aiming for approximately 2 lakh new patients in FY’28.
- Expansion plans include operationalizing around 140-150 additional hospital beds by March 2027.
- Revenue targets are set at Rs. 170 to Rs. 180 crore for FY’27 and Rs. 250 to Rs. 300 crore by FY’28.
2 more points from Vaidya Sane Ayurved Laboratories Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Vaidya Sane's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Q-Line Biotech (Q4 FY26)
Shift towards more manufacturing with gross margins of 60-65% for reagents supporting profitability improvement (Page 7, 6). Key concall takeaways from Q-Line…
- OSEL Devices (Q4 FY26)
PAT growth was 45.7% in FY26; management is optimistic about sustaining or improving profitability and EPS in coming years. Key concall takeaways from OSEL…
- Vasa Denticity Ltd (Q4 FY26)
The company has a debt line of ₹15 crore available from financial partners. Key concall takeaways from Vasa Denticity Ltd's Q4 FY26 earnings call — and how it…
- QMS Medical Allied Services Ltd (Q4 FY26)
INR 13 crores in FY26 to INR 18-20 crores in FY27. Key concall takeaways from QMS Medical's Q4 FY26 earnings call — and how it ranks against sector peers.
Arthneeti Pro · Annual
Vaidya Sane Ayurved Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vaidya Sane Ayurved Laboratories Ltd Q4 FY26 results?
FY'27 revenue target: Rs. Targeting EBITDA margin of near 15% by FY 2027, progressing towards 20% margin by FY 2028. - Revenue expected to grow to Rs.
What is Vaidya Sane Ayurved Laboratories Ltd share price analysis?
Vaidya Sane Ayurved Laboratories Ltd currently shows a below-average growth signal. The stock trades at a P/E of 16.9 with a market cap of ₹152 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vaidya Sane Ayurved Laboratories Ltd planning capital expenditure?
Preferential allotment funds received are currently in Fixed Deposit (FD) and have not been utilized yet; expected full funding to arrive over about 12 months (Page 20).
Keep Vaidya Sane Ayurved Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.